Cartesian Therapeutics Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Cartesian Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $34.57. The average 1-year stock price forecast is 258.98% higher than the current stock price, while the lowest is $16 (+66.15%) and the highest is $44 (+356.91%).

Price Target: $34.57 (+258.98%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$16	$34.57	$39	$44
Change	+66.15%	+258.98%	+304.98%	+356.91%

Analyst Ratings

The average analyst rating for Cartesian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	6	6	7	7	7	7
Buy	1	1	1	1	1	1
Hold	2	2	1	1	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	9	9	9	9	8	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Uy Ear Mizuho Securities	Mizuho Securities	Buy Reiterates $40	Buy	Reiterates	$40	+315.37%	Jun 10, 2026
Gil Blum Needham	Needham	Buy Reiterates $40	Buy	Reiterates	$40	+315.37%	Jun 9, 2026
Martin Fan Wedbush	Wedbush	Buy Maintains $38	Buy	Maintains	$38	+294.60%	May 28, 2026
Thomas Smith Leerink Partners	Leerink Partners	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	May 27, 2026
Mitchell Kapoor H.C. Wainwright	H.C. Wainwright	Buy Maintains $25	Buy	Maintains	$25	+159.61%	May 26, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

552.25K

from 2.80M

-80.26%

from 2.80M

Revenue Next Year

401.50K

from 552.25K

-27.30%

from 552.25K

EPS This Year

-3.35

from -4.99

EPS Next Year

-2.68

from -3.35

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	85.08M	110.78M	26.00M	38.91M	2.80M	552.25K
Revenue Growth	-	30.21%	-76.53%	49.64%	-92.81%	-80.26%
Gross Profit	16.34M	38.40M	-39.66M	-5.99M	-55.24M	552.25K
Gross Margin	19.21%	34.66%	-152.50%	-15.40%	-1,974.87%	100.00%
Operating Income	-4.60M	14.54M	-74.41M	-35.52M	-86.71M	-111.28M
Net Income	-25.69M	35.38M	-219.71M	-77.42M	-130.30M	-122.35M
EPS	-	-	-	-	-4.99	-3.35
Free Cash Flow	-	22.24M	28.91M	-59.67M	-55.62M	-109.00M
No. Analysts	-	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	1.9M
Avg	552,250
Low	78,000

Revenue Growth

Revenue Growth	2026	2027	2028
High	-32.1%
Avg	-80.3%
Low	-97.2%

EPS Forecast

EPS	2026	2027	2028
High	-3.35
Avg	-3.35
Low	-3.35

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-